Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Elliott Wave reversals


Bookmark and Share

 "Bottom line, the bear market is back in all the major averages," says Steven Hochberg, editor of The Elliott Wave Financial Forecast. Here's his technical guidelines for the key indices.

"The Dow saw a big reversal from another failed key trendline test at its May 2nd high. We previously forecast that if the index vaulted above its resistance lines on expanding breadth and increasing volume, that would be a bullish sign.

"However, volume continued to decline as the high approached and the NYSE cumulative advance/decline lin showed a clear loss of internatinal strength as breadth continued to contract.

Advertisement
Banner

"Technically, breadth deteriorated further, and the NYSE cumulative total actually broke through the bottom of a narrowing trangle.

"This is a key break that shows the characteristic negative breadth of a third wave decline is grabbing hold. As wave 3 accelerates lower, the declines should swamp advances, exceeding the extreme set last November.

"A move through the 12,750 area, a resistance level that includes the peaks of February 1 and 27 and April 7 as well as the May 9 low, is critically important. The comparable May 9 lows in the S&P, 1384, NASDAQ Composite, 2429, and NASDAQ 100, 1947, have yet to fall. Once they do, the race to much lower levels should be on.

"The next key downside test will come at the April 15 low, which is 12,269.8 in the Dow (1324.35 in the S&P, 2266.2 in the Composite and 1776.5 in the NASDAQ 100). A decline to this level in the Dow will be a .618 retracement of the rise through May 2-19.

"Once this low is out of the way, the dip-buyers will suddenly realize that they are close to losing all of their 'once-in-lifetime' gains and the selling will begin in earnest.

"The S&P 500 also stalled out after breaking though a previous fourth wave. Its quick reversal took out the rising trendline under wave (1) and brought it to rest just above another declining trendline that rides down on top of its October and wave 2 peaks.

"This level should give way soon and give rise to the assault on the key resistance levels cited above. It would take a rise through Monday’s peak at 1440 to alter this forecast.

"The NASDAQ 100's  momentum profile is already starting to resemble the downside look that it sported last November, the most powerful part of wave (1) down. In other words, the downside snowball is doing exactly what it is supposed to do in a third wave, accelerating.

"In the Composite, the resistance provided by the 200-day moving average and a preceding fourth wave of wave 3 down proved formidable. It will take a rise back through the wave C of (2) high at 2551.4 (2050.79 in the NASDAQ 100) to force a recount of this wave structure."


Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary